From: Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
 | Sputum status at the end of anti-TB treatment | aP-value | ||
---|---|---|---|---|
Smear negative n/N (%) | Culture negative n/N (%) | Culture positive n/N (%) | ||
Age, years | ||||
 16–35 | 144/144 (100) | 136/144 (94.4) | 8/144 (5.6) | .708 |
 36–55 | 44/44 (100) | 40/44 ((90.9) | 4/44 (9.1) | .999 |
 56–76 | 16/16 (100) | 16/16 (100) | 0/16 (0) | .998 |
Male | 94/94 (100) | 88/94 (93.6) | 6/94 (6.3) | .585 |
Female | 109/109 (100) | 103/109 (93.5) | 6/109 (5.5) | Â |
Smoker | 14/204 (6.8) | 14/14 (100) | 0/14 (0) | .999 |
Diabetes | 11/204 (5.3) | 11/11 (100) | 0/11 (0) | .999 |
bBacillary load before treatment | ||||
 Scanty | 20/204 (9.8) | 18/20 (90.0) | 2/20 (10.0) | .661 |
 + 1 | 117/204 (57.4) | 109/117 (93.2) | 8/117 (6.8) | .382 |
 + 2 | 37/204 (18.1) | 36/37 (97.3) | 1/37 (2.7) | .661 |
 + 3 | 30/204 (14.7) | 29/30 (96.7) | 1/30 (3.3) | .815 |
Smear positivity at 2 M | 3/204 (1.5) | 3/3 (100) | 0/3 (0) | 1.00 |
Chest X-ray | ||||
 Cavitary lesions | 7/102 (6.9) | 6/7 (85.7) | 1/7 (14.3) | .265 |
 Non-cavitary infiltrates | 95/102 (93.1) | 91/95 (95.8) | 4/95 (4.2) |  |
History of contact | ||||
 cRecent | 41/204 (20.0) | 36/41 (87.8) | 5/41 (12.2) | .08 |
 dPrevious | 39/204 (19.2) | 39/39 (100) | 0/39 (100) | .998 |
 No history of contact | 124/204 (60.8) | 119/124 (95.9) | 5/124 (4.1) | .897 |
Income | ||||
 Low | 109/204 (53.4) | 102/109 (93.6) | 7/109 (6.4) | .985 |
 Middle | 9/204 (4.5) | 9/9 (100) | 0/9 (0) | .862 |
 Unknown | 86/204 (42.1) | 81/86 (94.2) | 5/86 (5.8) | .999 |
Medicines in the continuation Phase | ||||
 INH + Rifampicin | 103/204 | 4/103 (3.9) | 99/103 (96.1) | .177 |
 INH+ Rifampicin +Ethambutol | 101/204 | 8/101 (7.9) | 93/101 (92.1) |  |